Project Grant HT94252410749

Grant Award Summary Cincinnati Children's Hospital Medical Center received a $743,776 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, awarded September 11, 2025, with completion targeted for August 31, 2033. The award supports research to elucidate the mechanisms of focal epileptogenesis in mtoropathies—a class of developmental disorders caused by...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, provides $158,750.00 to the University of Texas at Austin to conduct research on the function of the CACNA2D4 gene and its role in inherited retinal dystrophies. The overarching goal is to gain insight into the pathophysiological mechanisms of CACNA2D4-associated inherited retinal disorders by elucidating the structure-function relationships of the A2D-4 protein, which is...

Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant of $221,050 to Boston Children's Hospital, effective July 1, 2025 through January 2, 2028, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The award supports research investigating neuronal primary cilia dysfunction in tuberous sclerosis complex (TSC), a genetic disorder characterized by tumor growth and severe...

Federal Project Grant Award Summary Yale University received a $921,875 Project Grant award dated May 23, 2025, through the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The award supports research investigating Filamin A (FLNA) as a novel therapeutic target for treating seizures in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia Type II (FCDII). The...

Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Translational Genomics Research Institute (TGen) a Project Grant of $543,351 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) beginning August 1, 2025, with completion scheduled for July 31, 2027. The award funds research to develop and characterize a novel transgenic mouse model designed to elucidate the molecular mechanisms of Leigh...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 will provide $463,150 to The Regents of the University of California, San Francisco (UCSF) to establish proof-of-concept for enzyme replacement therapy (ERT) as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome (SPLIS), an ultra-rare and often lethal metabolic disorder. The project aims to demonstrate the efficacy of ERT in preserving kidney function and...

Trustees of Tufts College, doing business as Tufts University School of Medicine, received a $453,750 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The funding will support research to define the potential of gene therapy to correct motor disabilities associated with CTNNB1 syndrome, a rare genetic disorder characterized by intellectual...

The National Science Foundation (NSF) awarded a $999,255 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Tacit Therapeutics, Inc. The funding supports the development of a safe and effective RNA editing-based treatment for Dravet syndrome, a rare and devastating form of pediatric epilepsy. The project aims to replace defective sequences in the SCN1A gene, which is the primary genetic cause of Dravet syndrome, using a non-immunogenic RNA...

This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $148,942 to the Westfaelische Wilhelms-Universitaet Muenster in Germany to conduct research on identifying and characterizing the guanine nucleotide exchange factor (GEF) for the small GTPase Rheb as a novel target for treating tuberous sclerosis complex (TSC). The two-year award, running from July 1, 2024 to June 30, 2026, will support the university's...

This $488,507 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports pre-clinical translational research to investigate targeting synaptic dysfunction as a potential disease-modifying therapy for the rare neurological condition lissencephaly. The award to the University of California, Irvine will fund a 5-year research project that combines...